A strong message is needed to address the issue of HCC recurrence after DAA therapy

Journal of Hepatology

Volumn 65, Issue 6, 2016, Pages 1268-1269

  Kolly, Philippe ^a,b   Dufour, Jean François ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; HUMAN; LETTER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; LIVER TUMOR; TUMOR RECURRENCE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 84994761074     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.032     Document Type: Letter

References (5)

1. [1] Pol, S., Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts). J Hepatol 65 (2016), 734–740.
2. [2] Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 (2016), 719–726.
3. [3] Buonfiglioli, F., Conti, F., Andreone, P., Crespi, C., Foschi, F., Lenzi, M., et al. Development of hepatocellular carcinoma in hcv cirrhotic patients treated with direct acting antivirals. J Hepatol, 62, 2016, LBP506.
4. [4] Torres, H.A., Vauthey, J.-N., Economides, M.P., Mahale, P., Kaseb, A., Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment. J Hepatol 65 (2016), 862–864.
5. [5] Cammà, C., Cabibbo, G., Craxì, A., Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol 65 (2016), 861–862.